1. EvaluatePharma
®
World Preview 2016,
Outlook to 2022
Worldwide prescription
drug sales to grow at
6.3% (CAGR)
2016-2022
Worldwide pharmaceutical R&D spend
expected to grow by 2.8% (CAGR) to
$182bn in 2022 Biologics to contribute
50% of the Top 100 product sales by 2022.
50% of the 2022
increase in sales to
come from R&D
projects (+$169bn).
Leaderboard
Sales Roche or Novartis Roche & Novartis compete for No.1 with $52bn total worldwide prescription sales in 2022.
Drug Opdivo No.1 drug in 2022 with sales of $14.6bn but challenged by Revlimid.
NPV Roche Highest valued pipeline (NPV) at $43b in 2022.
© Copyright 2016 Evaluate Ltd. All rights reserved.
No.1 Product
USA
Humira (AbbVie) with
$10.7bn sales in 2022
No.1 Brand
EUROPE
Xarelto with €2.5bn
sales in 2022
Pharma Innovation
Top
Sellers
Highest Value Pipeline (NPV) in 2022:
Roche forecast with highest valued
pipeline (NPV) at $43bn in 2022
Top Value Creator: Gilead forecast to be
top value creator in 2022 based on 2015
sales from recently launched products.
Value Creators: Top 10 Pipelines NPV, $m Commercial innovation – Best selling
products after 2 years from launch
Analysis based on products launched
after January 2010
Company Pipeline NPV, $m
1. Roche 43,171
2. Novartis 24,091
3. AstraZeneca 23,160
4. Eli Lilly 19,677
5. AbbVie 19,364
6. Pfizer 18,214
7. Sanofi 17,699
8. Celgene 16,246
9. Biogen 13,621
10. Johnson & Johnson 13,157
Harvoni
(Gilead)
$6,362m
Sovaldi
(Gilead)
$5,461m
Tecfidera
(Biogen)
$3,228m
Year 2 WW Sales $m

2. Evaluate Headquarters
Evaluate Ltd.
11-29 Fashion Street
London E1 6PX
United Kingdom
T +44 (0)20 7377 0800
F +44 (0)20 7539 1801
Evaluate North America
EvaluatePharma USA Inc.
15 Broad Street, Suite 401
Boston, MA 02109, USA
T +1 617 573 9450
F +1 617 573 9542
Evaluate Japan
Evaluate Japan KK
Akasaka Garden City 4F
4-15-1 Akasaka, Minato-ku
Tokyo 107-0052, Japan
T +81 (0)80 1164 4754
www.evaluate.com
Evaluate is the trusted provider of commercial intelligence including
product sales and consensus forecasts to 2022 for commercial teams and
their advisors within the global life science industry. We help our clients
make high value decisions through superior quality, timely, must-have
data and insights, combined with personalised, expert client support.
EvaluatePharma®
delivers exclusive consensus sales forecasts and
trusted commercial insight into biotech and pharmaceutical performance.
@EvaluatePharma
EvaluateMedTech®
sets a new standard in commercial analysis and
consensus forecasts of the global medical device and diagnostic industry.
@EvaluateMedTech
EvaluateClinical Trials®
delivers unique clinical trial intelligence expertly
curated to efficiently analyse the global clinical trial landscape.
@EPClinicalTrial
EP Vantage an award winning editorial team, provides daily commentary
and analysis with fresh perspectives and insight into current and future
industry trends.
@EPVantage
Evaluate Custom Services provides customised solutions to help
you access, analyse and manage the information you need to support
effective decision-making.
The Evaluate services enable the life science community to make sound
business decisions about value and opportunity.
Request
a demo
today
Download
Report